Summary:
- The article discusses the clinical data of IBI363, a first-in-class PD-1/IL-2 bias bispecific antibody fusion protein, combined with bevacizumab in the treatment of advanced colorectal cancer. This data was presented at the 2024 ESMO Congress.
- IBI363 is a novel bispecific antibody that targets both PD-1 and IL-2, aiming to enhance the anti-tumor immune response by promoting the activation and proliferation of effector T cells while suppressing regulatory T cells.
- The combination of IBI363 and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, showed promising results in terms of safety and efficacy in patients with advanced colorectal cancer, a disease with a high unmet medical need.